This study aims to collect convalescent plasma and use it as experimental treatment in critically ill Covid-19 patients in order to reduce mortality and length of stay in intensive care unit.
This study aims to use convalescent plasma as experimental treatment in critically ill
Covid-19 patients in order to reduce mortality and length of stay in intensive care unit.
Donors must have anti-SARS CoV2 antibodies. Recipients must be critically ill Covid-19
patients on mechanical ventilation.
Biological: Convalescent plasma
Convalescent plasma from patients recovering from Covid-19 and which had anti-SARS-Cov-2 antibodies
Inclusion Criteria:
- Age: 18 years or more.
- Patient with Covid-19 confirmed with nuclear acid testing
- Critically ill patients with Covid-19 on mechanical ventilation. Potencially
critically ill patients (with acute respiratory distress syndrome, septic shock and/or
multiple organ failure) with Covid-19.
- Diagnosed with acute respiratory distress syndrome.
- Informed consent.
Exclusion Criteria:
- No consent.
- Symptoms for a period longer than 20 days.
- Not detectable by acid nuclear testing within 48 hours prior to elegibility.
- Descompensated congestive heart failure, in which receiving 500ml of intrasvascular
volume signifies a life risk.
- History of severe adverse events or anaphylaxis to plasma components
Hospital Francisco Javier Muñiz
Ciudad Autonoma de Buenos Aire, Argentina
Carlos A Gonzalez, MD, Principal Investigator
Hospital de Infecciosas Francisco Javier Muniz